Clinical trials in womens cancers

女性癌症的临床试验

• 批准号: 9556639
• 负责人: Christina Annunziata
• 金额: $ 28.69万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9556639
• 关键词: Apoptosis; Autologous; BAY 54-9085; Blood; Clinic; Clinical; Clinical Data; Clinical Trials; Collection; Dasatinib; Development; Enrollment; Goals; Greater sac of peritoneum; Growth Factor; Hereditary Breast Carcinoma; Interferon Type II; Interferon-alpha; Investigation; Malignant Neoplasms; Malignant neoplasm of ovary; Mutation; Patients; Peritoneal; Phase; Phase I Clinical Trials; Pleural; Process; Protein Family; Protocols documentation; Publishing; Research Personnel; Specimen; Testing; Therapeutic; Woman; angiogenesis; bevacizumab; effusion; follow-up; inhibitor-of-apoptosis protein; mimetics; monocyte; phase 1 study; safety testing; treatment trial

In 2014, I became the Acting Clinical Director of the Women's Malignancies Branch. We are currently in the process of analyzing specimens and data from clinical trials 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; and 09-C-0019 phase 1 study of bevacizumab and dasatinib. In 2016 we published the results of clinical trial 12C0191 - SMAC-mimetic birinapant phase 2 in ovarian cancer. Study 09C0019 - Bevacizumab and Dasatinib phase 1 trial is closed to accrual but has 1 patient in follow up. A blood collection study 14-C-0056 closed; in its place, we opened 17-C-0100 to collect blood and effusions (pleural and peritoneal) from patients with cancer enrolled on other protocols at the NCI. An ongoing treatment trial, 17-C-0011, will test the safety of administering autologous monocytes stimulated with both interferon alpha and gamma into the peritoneal cavity of women with ovarian cancer. Additional clinical trials are under development at the concept stage or are under review by IRB. Within the WMB, I collaborate with Jung-min Lee and Stan Lipkowitz as Associate Investigator on several other clinical trials.

2014年，我成为女性肿瘤分支的代理临床主任。我们目前正在分析来自临床试验07 C 0058-贝伐单抗和索拉非尼治疗卵巢癌的2期研究以及贝伐单抗和达沙替尼的1期研究09-C-0019的标本和数据。2016年，我们发表了卵巢癌临床试验12 C 0191- SMAC-mimetic birinapant II期的结果。研究09 C 0019-贝伐珠单抗和达沙替尼1期试验已结束招募，但有1例患者正在随访。血液采集研究14-C-0056关闭;取而代之，我们打开17-C-0100，从NCI其他方案入组的癌症患者中采集血液和积液（胸膜和腹膜）。一项正在进行的治疗试验17-C-0011将测试用干扰素α和γ刺激的自体单核细胞进入卵巢癌妇女腹膜腔的安全性。其他临床试验正在概念阶段开发或正在接受IRB审查。在WMB，我与Jung-min Lee和Stan Lipkowitz合作，担任其他几项临床试验的副研究员。